Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells

P97/CDC-48: Proteostasis control in tumor cell biology

(2013) Delphine Fessart et al.   CANCER LETTERS

p97 complexes as signal integration hubs

(2012) Hemmo Meyer   BMC BIOLOGY

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

(2012) P. Kharaziha et al.   CANCER RESEARCH

DangER: protein ovERload. Targeting protein degradation to treat myeloma

(2012) L. I. Aronson et al.   HAEMATOLOGICA

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

(2012) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death

(2012) P. Yi et al.   MOLECULAR CANCER THERAPEUTICS

Development of p97 AAA ATPase inhibitors

(2011) Tsui-Fen Chou et al.   Autophagy

Recent advances in p97/VCP/Cdc48 cellular functions

(2011) Kunitoshi Yamanaka et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells

(2011) S. Mannava et al.   BLOOD

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

The case for therapeutic proteostasis modulators

(2011) Neeraj Vij   EXPERT OPINION ON THERAPEUTIC TARGETS

Inhibition of Endoplasmic Reticulum-associated Degradation Rescues Native Folding in Loss of Function Protein Misfolding Diseases

(2011) Fan Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Cdc48/p97 Mediates UV-Dependent Turnover of RNA Pol II

(2011) Rati Verma et al.   MOLECULAR CELL

Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress

(2011) Ira Tabas et al.   NATURE CELL BIOLOGY

Critical Role of VCP/p97 in the Pathogenesis and Progression of Non-Small Cell Lung Carcinoma

(2011) Christopher W. Valle et al.   PLoS One

Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways

(2011) T.-F. Chou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes

(2010) E. David et al.   BLOOD

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress

(2010) H. W. Auner et al.   BLOOD

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

(2010) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The ERAD Inhibitor Eeyarestatin I Is a Bifunctional Compound with a Membrane-Binding Domain and a p97/VCP Inhibitory Group

(2010) Qiuyan Wang et al.   PLoS One

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

Biogenesis of secretory organelles during B cell differentiation

(2009) Semra J. Kirk et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

Effect of autophagy on multiple myeloma cell viability

(2009) B. Hoang et al.   MOLECULAR CANCER THERAPEUTICS

The Otubain YOD1 Is a Deubiquitinating Enzyme that Associates with p97 to Facilitate Protein Dislocation from the ER

(2009) Robert Ernst et al.   MOLECULAR CELL

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

(2009) Q. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of p97-dependent Protein Degradation by Eeyarestatin I

(2008) Qiuyan Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential

(2008) Neeraj Vij   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

One step at a time: endoplasmic reticulum-associated degradation

(2008) Shruthi S. Vembar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The Recognition and Retrotranslocation of Misfolded Proteins from the Endoplasmic Reticulum

(2008) Kunio Nakatsukasa et al.   TRAFFIC